Kannenberg A, Seidinger S
Otto Bock Healthcare LP, Austin, Texas, USA.
Otto Bock Healthcare GmbH, Vienna, Austria.
Can Prosthet Orthot J. 2021 Sep 21;4(2):35298. doi: 10.33137/cpoj.v4i2.35298. eCollection 2021.
The rapid advancement of prosthetic and orthotic (P&O) technology raises the question how the industry can ensure that patients have access to the benefits and providers get paid properly and fairly by healthcare payers. This is a challenge that not only P&O but all areas of health technology face. In many areas of medicine and health products, such as drugs and medical devices, health-technology assessments (HTA) have become a standard procedure in the coverage and reimbursement process. In most countries, P&O is lagging behind that development, although some countries have already formalized HTA for prosthetic and orthotic products and may even use cost-effectiveness analyses to determine pricing and payment amounts. This article gives an overview on the coverage and reimbursement processes in the United States, Canada, Germany, France, Sweden, the United Kingdom, Poland, Japan, and China. This selection reflects the variety and diversity of coverage and reimbursement processes that the P&O industry faces globally. The paper continues with an overview on the necessary research and investment efforts that manufacturers will have to make in the future, and contemplates the likely consequences for the manufacturer community in the market place. Health economics may help support the transition from price-based to value-based coverage and reimbursement but will come at considerable costs to the industry.
假肢与矫形器(P&O)技术的迅速发展引发了一个问题:该行业如何确保患者能够受益,以及医疗服务支付方能够合理、公平地向供应商支付费用。这不仅是P&O行业面临的挑战,也是所有健康技术领域面临的挑战。在药品和医疗设备等许多医学和健康产品领域,卫生技术评估(HTA)已成为覆盖范围和报销流程中的标准程序。在大多数国家,P&O行业在这方面的发展滞后,尽管一些国家已经将针对假肢和矫形器产品的卫生技术评估正式化,甚至可能使用成本效益分析来确定定价和支付金额。本文概述了美国、加拿大、德国、法国、瑞典、英国、波兰、日本和中国的覆盖范围和报销流程。这一选择反映了P&O行业在全球面临的覆盖范围和报销流程的多样性。本文接着概述了制造商未来必须进行的必要研究和投资努力,并思考了对市场中制造商群体可能产生的影响。卫生经济学可能有助于支持从基于价格的覆盖范围和报销向基于价值的转变,但这将给该行业带来相当大的成本。